Publications

Lewis KA, Stroebel B, Zhang L, Aouizerat B, Mattis A, Flowers E. MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program. Research square. 2024. PMID: 38313262


Li Zhang, PhD

Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. PMID: 38215355


Terence Friedlander, MD

Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024. PMID: 38212070


Vadim Koshkin, MD

Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024. PMID: 38212070


Jonathan Chou, MD, PhD

Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024. PMID: 38212070


Rahul Aggarwal, MD

Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. Journal for immunotherapy of cancer. 2024. PMID: 38212126


Alan Venook, MD

Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024. PMID: 38212070


Terence Friedlander, MD

Friedman CF, D'Souza A, Bello Roufai D, Tinker AV, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko ME, Oaknin A, Spanggaard I, Shapiro GI, ElNaggar AC, Panni S, Ravichandran V, Frazier AL, DiPrimeo D, Eli LD, Solit DB. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. Gynecologic oncology. 2024. PMID: 38211393


Michelle Melisko, MD

Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. Large tandem duplications in cancer result from transcription and DNA replication collisions. medRxiv : the preprint server for health sciences. 2024. PMID: 38260434


Alan Ashworth, PhD

Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. Large tandem duplications in cancer result from transcription and DNA replication collisions. medRxiv : the preprint server for health sciences. 2024. PMID: 38260434


Jonathan Chou, MD, PhD

Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, Banerjee A, Chastain K, Perales-Puchalt A, Stephenson T, Uhlar C, Kobos R, van der Holt B, Kruyswijk S, Kuipers MT, Groen K, Vishwamitra D, Skerget S, Cortes-Selva D, Doyle M, Zaaijer HL, Zweegman S, Verona RI, van de Donk NWCJ. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood advances. 2024. PMID: 38052042


Thomas Martin, MD

Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast cancer research and treatment. 2024. PMID: 38194132


Melanie Majure, MD

Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast cancer research and treatment. 2024. PMID: 38194132


John Park, MD

Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast cancer research and treatment. 2024. PMID: 38194132


Hope Rugo, MD

Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast cancer research and treatment. 2024. PMID: 38194132


Jo Chien, MD

Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast cancer research and treatment. 2024. PMID: 38194132


Michelle Melisko, MD

Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. PMID: 38194616


Hope Rugo, MD

Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen BK, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko AH, Fong L, Keenan BP. Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer. Cancer Research Communications. 2024. PMID: 38181044


Lawrence Fong, MD

Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen BK, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko AH, Fong L, Keenan BP. Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer. Cancer Research Communications. 2024. PMID: 38181044


Li Zhang, PhD

Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen BK, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko AH, Fong L, Keenan BP. Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer. Cancer Research Communications. 2024. PMID: 38181044


Andrew Ko, MD